Scroll Up
Scroll Down
Play Play Play Play
Unregistered User
Click here if this is not your Personal Edition
 
Contact Us | Free E-Mail Updates | Journals | Register a colleague
 
 
Diabetes
 
   
 
SEARCH   
Doctor's Guide Free CME
Medline
Congress Resource Centre
 

 EXPLORE :
   Most Read News
 All News  All News
 All Webcasts / CME  All Webcasts / CME
 All Cases  All Cases
 Congress Resource Centre  Congress Resource Centre
 All Medical Resources  All Medical Resources
 Medical  My Personal Edition



Warning | Privacy

 

 
 Recent news - Diabetes
    Glucose Levels Affect Total Joint Replacement Outcomes in Patients With Diabetes - (DGNews)
    Endocrine Society Responds to Insulin Glargine Studies With Recommendations - (DGNews)
    TopAbstracts in Diabetes 06/30/2009 - (DGNews)
    Certain Biomarkers Have Limitations in Predicting Cardiovascular Events - (DGNews)
    Glucose Challenge Test Is Accurate for Diabetes, Prediabetes Screening - (DGNews)

    News archive

     Recent webcasts/CME - Diabetes
    • Matching Treatment to Need in Type 2 Diabetes: Using Incretin-Based Oral Therapies Across the Clinical Spectrum
    • Achieving Glycemic Control After Standard Therapy Has Failed
    • The Challenge of Type 2 Diabetes: Emerging Options for Improving Glycemic Control
      Addressing Patient Challenges to Diabetes Treatment Through the Use of Incretin-based Therapies
      Management of Hyperglycemia in Acute-Care Settings and the Transition to Ambulatory Care

      Webcasts/CME archive

       Recent cases - Diabetes
        Improvement of the Diabetic Foot Upon Testosterone Administration to Hypogonadal Men with Peripheral Arterial Disease. Report of Three Cases
        Caudal Regression Syndrome and Popliteal Webbing in Connection with Maternal Diabetes Mellitus: A Case Report and Literature Review
        Atypical Onset of Diabetes in a Teenage Girl: A Case Report
        Painful Swelling in the Thigh: Diabetic Muscle Infarction
        Atypical Ketosis-Prone Diabetes

        Cases archive
          




        my personal edition > diabetes > news
        divider

          E-Mail this DGDispatch to a colleague

        DGDispatch


        Pregabalin Significantly Reduces Pain of Diabetic Peripheral Neuropathy: Presented at ADA

        By Bruce Sylvester

        SAN DIEGO, CA -- June 15, 2005 -- For the pain of diabetic peripheral neuropathy, pregabalin treatment showed significant efficacy over placebo after 1 day of treatment, researchers reported here on June 12th at the 65th Scientific Sessions of the American Diabetes Association (ADA).

        "And it didn't matter which of the effective doses a patient used. The lowest dose showed efficacy within 24 hours," said presenter and lead investigator Brett Stacey, MD, Medical Director, Comprehensive Pain Center, and Associate Professor of Medicine, Oregon Health and Science University, Portland, Oregon, United States. "So patients can expect relief very, very quickly with this drug and the relief continues to increase over the first week. It also appears to be well tolerated."

        Dr. Stacey and colleagues gathered retrospective data from six randomized, double-blind, placebo-controlled trials of patients with painful diabetic peripheral neuropathy. They analyzed data for time to significant pain reduction after initiation of pregabalin treatment according to target dosing and titration speed. Treatment cohorts were as follows: 473 placebo and 873 pregabalin (all doses).

        Pregabalin subgroups were as follows: low (minimum therapeutic dose: 150 mg/day); "slow" (300 and 600 mg/day, titrated slowly so that less than half of target dose was reached after the fourth day of treatment) and "fast" (300 and 600 mg/day titrated rapidly so that at least half of target dose was reached on or before the fourth day of treatment).

        For each subgroup, the investigators assessed data for time to significant effect by measuring changes from baseline in daily pain scores taken from patient-recorded diaries (11-point scale; 0=no pain; 10=worst possible pain).

        Significant pain score reductions appeared as early as day 1 for the three pregabalin groups. Reductions in daily pain score were -2.04 for "low" dosing, -2.56 for "slow" dosing, and -2.60 for "fast" dosing of pregabalin, compared to -1.49 for patients on placebo (P < .0081).

        The authors concluded that pregabalin demonstrated statistically significant improvement over placebo in painful diabetic peripheral neuropathy patients after 1 day of treatment."

        Dr. Stacey noted that although the US Food and Drug Administration approved pregabalin in December of 2004 for treatment of the pain associated with diabetic peripheral neuropathy, it is not yet available in US drugstores. "We expect to see it here in late summer or early fall," he said.


        [Presentation title: Pregabalin Significantly Reduces the Pain Associated with Diabetic Peripheral Neuropathy by Day One of Treatment. Abstract 602-P]



        E-Mail this DGDispatch to a colleague   To print, use this version






        All contents Copyright (c) 1995-2009 Doctor's Guide Publishing Limited. All rights reserved.



        The NTK initiative. Physicians helping physicians identify Need-To-Know science
           Feedback
        Please rate this article: Strongly DISAGREE...Strongly AGREE NTK logo
        Question 1 - Physicians need to become aware of this information as soon as possible. Question 2 - This information is likely to have an impact on the way physicians practice medicine.
        1
        2
        3
        4
        5
        6
        7
        Send